Neogenomics (NEO) Common Equity (2010 - 2026)

Neogenomics (NEO) has reported Common Equity for 17 consecutive years, with $828.8 million the latest figure, recorded in Q1 2026.

• Common Equity for Q1 2026 came in at $828.8 million, down 6.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $828.8 million (down 6.7% YoY), and the FY2025 annual result was $836.6 million, down 7.29% from the prior year.
• Common Equity was $828.8 million for Q1 2026 at Neogenomics, down from $836.6 million in the prior quarter.
• Over five years, Common Equity peaked at $1.1 billion in Q1 2022 and troughed at $828.8 million in Q1 2026.
• Average Common Equity over 5 years is $932.1 million, with a median of $923.4 million recorded in 2024.
• The widest YoY moves for Common Equity: up 27.41% in 2022, down 10.93% in 2022.
• Over 5 years, Common Equity stood at $998.0 million in 2022, then declined by 5.66% to $941.5 million in 2023, then decreased by 4.16% to $902.3 million in 2024, then retreated by 7.29% to $836.6 million in 2025, then decreased by 0.93% to $828.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $828.8 million in Q1 2026, $836.6 million in Q4 2025, and $838.3 million in Q3 2025.